1. Home
  2. RNA
  3. RNA News

Latest Avidity Biosciences Inc. (RNA) News on January 19, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

11 days ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

11 days ago

Avidity Biosciences Plans to Submit First Biologics License Application This Year

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
RNA

PR Newswire

11 days ago

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?
RNA

Insider Monkey

18 days ago

Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

a month ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

a month ago

HC Wainwright Initiates Coverage on Avidity Biosciences With Buy Rating, $72 Price Target

RNA

MT Newswires

a month ago

Avidity Biosciences Insider Sold Shares Worth $1,040,384, According to a Recent SEC Filing

RNA

MT Newswires

a month ago

Avidity Biosciences Insider Sold Shares Worth $831,605, According to a Recent SEC Filing

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

2 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

2 months ago

RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

2 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
RNA

Zacks

2 months ago

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data

RNA Stock Hits Record High on Entering the Cardiac Disease Space
RNA

Zacks

2 months ago

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
RNA

Investor's Business Daily

2 months ago

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
RNA

PR Newswire

2 months ago

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
RNA

Simply Wall St.

2 months ago

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
RNA

Zacks

2 months ago

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
RNA

PR Newswire

2 months ago

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
RNA

Zacks

2 months ago

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for

An RNAi renaissance is creating a new generation of startups
RNA

BioPharma Dive

2 months ago

An RNAi renaissance is creating a new generation of startups

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
RNA

PR Newswire

3 months ago

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
RNA

PR Newswire

3 months ago

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

3 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
RNA

Investor's Business Daily

3 months ago

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

RNA

MT Newswires

3 months ago

Avidity Biosciences Insider Sold Shares Worth $1,349,259, According to a Recent SEC Filing

Why Avidity Biosciences Zoomed to a 12% Gain This Week
RNA

Motley Fool

3 months ago

Why Avidity Biosciences Zoomed to a 12% Gain This Week

FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
RNA

Pharmaceutical Technology

3 months ago

FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial

RNA

MT Newswires

4 months ago

Sector Update: Health Care Stocks Steady Premarket Thursday

RNA

MT Newswires

4 months ago

Avidity Biosciences Says FDA Lifted Partial Hold on Investigational Therapy for Neuromuscular Disease

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
RNA

PR Newswire

4 months ago

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)

Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024?
RNA

Insider Monkey

4 months ago

Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024?

Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?
RNA

Insider Monkey

4 months ago

Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

4 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

4 months ago

Goldman Sachs Initiates Avidity Biosciences at Buy

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

4 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

4 months ago

Avidity Biosciences Insider Sold Shares Worth $1,010,043, According to a Recent SEC Filing

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
RNA

PR Newswire

4 months ago

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month

Avidity Biosciences to Participate in Upcoming Investor Conferences
RNA

PR Newswire

5 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

RNA

MT Newswires

5 months ago

Barclays Initiates Avidity Biosciences at Overweight

RNA

MT Newswires

5 months ago

Evercore ISI Trims Price Target on Avidity Biosciences to $53 From $54, Keeps Outperform Rating

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA
RNA

BioPharma Dive

5 months ago

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA

RNA

MT Newswires

5 months ago

Avidity Biosciences Raises $345.1 Million From Upsized Public Offering

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RNA

MT Newswires

5 months ago

Avidity Biosciences Prices Stock Offering at $41 Per Share

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

RNA

MT Newswires

5 months ago

Avidity Biosciences Plans $250 Million Underwritten Public Offering of Shares

Avidity Biosciences Announces Proposed Public Offering of Common Stock
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Company News for Aug 13, 2024
RNA

Zacks

5 months ago

Company News for Aug 13, 2024

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
RNA

Zacks

5 months ago

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates

RNA

MT Newswires

5 months ago

Avidity Biosciences Q2 Net Loss Narrows, Revenue Drops

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
RNA

Investor's Business Daily

5 months ago

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
RNA

PR Newswire

5 months ago

Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights

RNA

MT Newswires

5 months ago

Chardan Research Adjusts Avidity Biosciences' PT to $60 From $45, Keeps Buy Rating

RNA

MT Newswires

5 months ago

Avidity Biosciences Says Del-zota Shows 'Significant' Dystrophin Production in Phase 1/2 Study

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial

RNA

MT Newswires

5 months ago

Avidity Biosciences Insider Sold Shares Worth $1,213,822, According to a Recent SEC Filing

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

3 Russell 2000 Growth Stocks That Could Be Worth the Risk
RNA

Motley Fool

6 months ago

3 Russell 2000 Growth Stocks That Could Be Worth the Risk

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

6 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity’s FSHD drug del-brax shows promise in Phase I/II trial
RNA

Clinical Trials Arena

7 months ago

Avidity’s FSHD drug del-brax shows promise in Phase I/II trial

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

7 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

7 months ago

Avidity Biosciences Insider Sold Shares Worth $1,255,040, According to a Recent SEC Filing

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
RNA

PR Newswire

7 months ago

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
RNA

Simply Wall St.

7 months ago

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
RNA

PR Newswire

7 months ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

7 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

7 months ago

Wells Fargo Raises Price Target on Avidity Biosciences to $75 From $50, Maintains Overweight Rating

RNA

MT Newswires

7 months ago

Avidity Biosciences Prices $400.9 Million Offering of Shares

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
RNA

PR Newswire

7 months ago

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
RNA

Zacks

7 months ago

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

RNA

MT Newswires

7 months ago

Avidity Biosciences Plans $300 Million Common Stock Offering

The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
RNA

Investor's Business Daily

7 months ago

The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
RNA

PR Newswire

7 months ago

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

RNA

MT Newswires

7 months ago

Sector Update: Health Care Stocks Softer Wednesday Afternoon

RNA

MT Newswires

7 months ago

Update: Avidity Biosciences Shares Jump as Muscle Disease Therapy Shows Promising Early Results

RNA

MT Newswires

7 months ago

Top Midday Gainers

RNA

MT Newswires

7 months ago

Chardan Raises Price Target on Avidity Biosciences to $45 From $33, Maintains Buy Rating

RNA

MT Newswires

7 months ago

Avidity Biosciences's Muscle Disease Therapy Shows Promising Early Results -- Shares Surge Pre-Bell

Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
RNA

BioPharma Dive

7 months ago

Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
RNA

GOBankingRates

7 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
RNA

Business Insider

7 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
RNA

Insider Monkey

7 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
RNA

Reuters

7 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

RNA

Insider Monkey

7 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow
RNA

AFP

7 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events
RNA

Investor's Business Daily

7 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments
RNA

The Wall Street Journal

7 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
RNA

ACCESSWIRE

7 months ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies
RNA

Business Insider

7 months ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
RNA

GlobeNewswire

7 months ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger
RNA

Motley Fool

7 months ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Unifor members vote to strike at Manitoba Hydro
RNA

CNW Group

7 months ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly
RNA

AFP

7 months ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires
RNA

Business Insider

7 months ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Here's what to do if you missed out on the massive 54% stock market rally since October 2022
RNA

Business Insider

7 months ago

Here's what to do if you missed out on the massive 54% stock market rally since October 2022

RNA

MT Newswires

7 months ago

Avidity Biosciences Insider Sold Shares Worth $767,780, According to a Recent SEC Filing

Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
RNA

PR Newswire

8 months ago

Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress

2 Potentially High-Reward Growth Stocks to Buy Right Now
RNA

Motley Fool

8 months ago

2 Potentially High-Reward Growth Stocks to Buy Right Now

Share on Social Networks: